On September 30, 2021, PDS Biotechnology Corporation delivered a notice of termination without cause to Seth Van Voorhees and removed him from his position as the Company’s principal financial officer and principal accounting officer. The company and Mr. Van Voorhees are continuing to discuss the terms of Mr. Van Voorhees separation from the Company. Frank Bedu-Addo, the Company’s Chief Executive Officer, will serve as the Company’s interim principal financial officer, and Janetta Trochimiuk, the Company’s controller, will serve as the interim principal accounting officer, in each case, until the Effective Date. On October 4, 2021, the Company entered into an Executive Employment Agreement with Matthew Hill, pursuant to which Mr. Hill will be appointed as the Company’s Chief Financial Officer, effective as of October 18, 2021 (the “ Effective Date”). On the Effective Date, Mr. Hill will serve as the Company’s principal financial officer and principal accounting officer. Mr. Hill, age 53, previously served as the Chief Financial Officer of Strata Skin Sciences, where he led the financial vision and strategy for the medical device company from May 2018 through October 2021. Immediately prior to joining Strata Skin Sciences, Mr. Hill served as the Chief Financial Officer of SS White Burs Inc., a privately held medical device manufacturer, from May 2010 until May 2018. Mr. Hill also served as the Chief Financial Officer of Velcera prior to its acquisition by the Perrigo Company, and EP Medsystems prior to its acquisition by St. Jude Medical, where he also served as the VP of Operations.